Could abemaciclib be the next weapon against Hard-to-Treat gut tumors?

NCT ID NCT03891784

Ongoing Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink or slow the growth of these tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (Verzenio), a CDK4/6 inhibitor taken orally
What this could lead to: If successful, this could provide a new treatment option for patients with advanced neuroendocrine tumors that have stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. The drug may not shrink tumors or improve survival, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell digestive system neuroendocrine neoplasm digestive system neuroendocrine tumor, grade 1/2 intestinal neuroendocrine neoplasm pancreatic neuroendocrine tumor small intestine neuroendocrine tumor, well differentiated, low or intermediate grade

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR FOREGUT NEUROENDOCRINE TUMOR HINDGUT NEUROENDOCRINE TUMOR LOCALLY ADVANCED UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM METASTATIC DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM MIDGUT NEUROENDOCRINE TUMOR PANCREATIC NEUROENDOCRINE TUMOR REFRACTORY DIGESTIVE SYSTEM NEUROENDOCRINE NEOPLASM

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
University of Colorado

Denver, Colorado, 80217, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.